Synchronous and Metachronous Breast and Ovarian Cancer: Experience From Two Large Cancer Center.
BRCA mutation
breast cancer
doublet tumors
metachronous cancer
ovarian cancer
synchronous cancer
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2020
2020
Historique:
received:
21
09
2020
accepted:
16
11
2020
entrez:
31
12
2020
pubmed:
1
1
2021
medline:
1
1
2021
Statut:
epublish
Résumé
We aimed to evaluate the clinico-pathological characteristics and survival outcomes of patients with synchronous or metachronous breast cancer (BC) and ovarian cancer (OC). Patients with synchronous or metachronous BC and OC were retrospectively identified at two large cancer centers. Clinico-pathological characteristics, Overall, 270 patients were included: n = 194 (72%) in In this cohort of patients with BC and OC, survival was dominated by OC related mortality. These data may be useful to plan and carry out adequate and timely surveillance programs and preventive measures.
Identifiants
pubmed: 33381461
doi: 10.3389/fonc.2020.608783
pmc: PMC7768039
doi:
Types de publication
Journal Article
Langues
eng
Pagination
608783Informations de copyright
Copyright © 2020 Tasca, Dieci, Baretta, Faggioni, Montagna, Nicoletto, Peccatori, Guarneri and Colombo.
Déclaration de conflit d'intérêts
GT has received fees from AstraZeneca, Tesaro and GSK for consultancy role and participation on advisory boards. MD has received fees from EliLilly for consultancy role and participation on advisory boards, fees from Genomic Health for consultancy role, fees from Celgene for participation on advisory. FP has received remuneration from Ipsen and fees from Roche and AstraZeneca for consultancy role and participation on advisory boards. VG has received fees from EliLilly, Roche, and Novartis. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
JAMA. 1972 Dec 25;222(13):1631-5
pubmed: 4678365
Gynecol Oncol. 2017 May;145(2):346-351
pubmed: 28314588
Br J Cancer. 1981 Nov;44(5):628-36
pubmed: 7317267
Gynecol Oncol. 2006 Oct;103(1):190-4
pubmed: 16569424
Cancer. 2013 Apr 1;119(7):1344-8
pubmed: 23165893
Clin Genet. 2014 Jan;85(1):43-8
pubmed: 24000781
Eur J Cancer. 2001 Nov;37(17):2229-34
pubmed: 11677112
Gynecol Oncol. 2004 Sep;94(3):796-802
pubmed: 15350375
Int J Cancer. 1995 Feb 8;60(4):464-70
pubmed: 7829259
Br J Cancer. 2016 Nov 8;115(10):1174-1178
pubmed: 27755534
Science. 1990 Dec 21;250(4988):1684-9
pubmed: 2270482
J Clin Oncol. 2008 Dec 1;26(34):5530-6
pubmed: 18955455
Breast Cancer Res Treat. 2012 Jul;134(1):353-62
pubmed: 22434525
JAMA. 2017 Jun 20;317(23):2402-2416
pubmed: 28632866
Breast Cancer Res Treat. 1996;38(3):305-11
pubmed: 8739084
Surg Gynecol Obstet. 1971 Oct;133(4):644-8
pubmed: 4328854
JAMA Surg. 2014 Dec;149(12):1306-13
pubmed: 25372568
Ann Oncol. 2011 Jun;22(6):1346-1352
pubmed: 21228333
Obstet Gynecol. 2012 Aug;120(2 Pt 1):235-40
pubmed: 22776961
Lancet. 2001 Oct 27;358(9291):1389-99
pubmed: 11705483
JAMA Oncol. 2016 Apr;2(4):482-90
pubmed: 26720728
JAMA. 2000 May 3;283(17):2260-5
pubmed: 10807385
CA Cancer J Clin. 2015 Mar;65(2):87-108
pubmed: 25651787
Natl Cancer Inst Monogr. 1985 Dec;68:219-42
pubmed: 4088299
Cancer Epidemiol Biomarkers Prev. 2012 Jan;21(1):134-47
pubmed: 22144499
Clin Endocrinol (Oxf). 1998 Dec;49(6):695-707
pubmed: 10209555
Lancet. 1994 Nov 5;344(8932):1250-4
pubmed: 7967985